Connect with us

International

CureVac to cut costs, starts GSK-partnered bird flu vaccine trial

CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.
It said Wednesday that 150 employees have…

Published

on

CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.

It said Wednesday that 150 employees have agreed to voluntarily leave the company. The news was first reported last month by German news outlet SWR. CureVac currently has more than 1,100 employees, according to the annual report.

CureVac said its reorganization will lead to savings starting in the second half of the year, and its cash runway is now set to extend into the fourth quarter of 2025. Its stock $CVAC was down about 8% on Wednesday morning.

In its fourth-quarter earnings update, the company also announced that its and GSK’s joint pandemic preparedness agreement with the German government would be terminated at the end of May. Germany had contracted the companies to supply mRNA-based vaccines in the event of a public health emergency. CureVac noted that plans to complete its vaccine manufacturing facility remain unaffected, and the site is expected to be certified in the second half of the year.

Thaminda Ramanayake

On June 1, CureVac will also be getting a new chief business officer. Thaminda Ramanayake was previously CBO at Affini-T Therapeutics.

CureVac also announced the start of a Phase 1/2 study of an H5N1 avian flu vaccine candidate as part of its collaboration with GSK to develop mRNA vaccines. There are escalating concerns about a bird flu pandemic in humans since the disease spread to dairy cows in the US. The FDA on Tuesday reported evidence of the virus in commercial pasteurized milk, but maintained that the pasteurization process is likely to inactivate the virus. The regulator said the commercial milk supply is still safe.

The avian flu vaccine study will test up to five dose levels compared to a placebo control in two groups of adults: those aged 18 to 64 years old, and adults aged 65 to 85.

CureVac’s partnership with GSK began in July 2020, and they were major players in the Covid-19 vaccine race until their vaccine failed a pivotal study and efforts flamed out. They are currently developing a seasonal mRNA flu vaccine, though the partners recently reported mixed data from a Phase 2 trial.

Read More

Continue Reading

International

CureVac to cut costs, starts GSK-partnered bird flu vaccine trial

CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.
It said Wednesday that 150 employees have…

Published

on

CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.

It said Wednesday that 150 employees have agreed to voluntarily leave the company. The news was first reported last month by German news outlet SWR. CureVac currently has more than 1,100 employees, according to the annual report.

CureVac said its reorganization will lead to savings starting in the second half of the year, and its cash runway is now set to extend into the fourth quarter of 2025. Its stock $CVAC was down about 8% on Wednesday morning.

In its fourth-quarter earnings update, the company also announced that its and GSK’s joint pandemic preparedness agreement with the German government would be terminated at the end of May. Germany had contracted the companies to supply mRNA-based vaccines in the event of a public health emergency. CureVac noted that plans to complete its vaccine manufacturing facility remain unaffected, and the site is expected to be certified in the second half of the year.

Thaminda Ramanayake

On June 1, CureVac will also be getting a new chief business officer. Thaminda Ramanayake was previously CBO at Affini-T Therapeutics.

CureVac also announced the start of a Phase 1/2 study of an H5N1 avian flu vaccine candidate as part of its collaboration with GSK to develop mRNA vaccines. There are escalating concerns about a bird flu pandemic in humans since the disease spread to dairy cows in the US. The FDA on Tuesday reported evidence of the virus in commercial pasteurized milk, but maintained that the pasteurization process is likely to inactivate the virus. The regulator said the commercial milk supply is still safe.

The avian flu vaccine study will test up to five dose levels compared to a placebo control in two groups of adults: those aged 18 to 64 years old, and adults aged 65 to 85.

CureVac’s partnership with GSK began in July 2020, and they were major players in the Covid-19 vaccine race until their vaccine failed a pivotal study and efforts flamed out. They are currently developing a seasonal mRNA flu vaccine, though the partners recently reported mixed data from a Phase 2 trial.

Read More

Continue Reading

International

Study finds X’s (formerly Twitter’s) community notes provide accurate, credible answers to vaccine misinformation

As the proliferation of misinformation continues to pose a significant challenge on social media platforms, a beacon of hope emerges in research from the…

Published

on

As the proliferation of misinformation continues to pose a significant challenge on social media platforms, a beacon of hope emerges in research from the University of California San Diego.

Credit: Screenshot by Qualcomm Institute, UC San Diego

As the proliferation of misinformation continues to pose a significant challenge on social media platforms, a beacon of hope emerges in research from the University of California San Diego.

A new study published in JAMA led by John W. Ayers, Ph.D., from the Qualcomm Institute within UC San Diego, finds that X’s Community Notes, a crowdsourced approach to addressing misinformation, helped counter false health information in popular posts about COVID-19 vaccines with accurate, credible responses.

“Since the World Health Organization declared an ‘infodemic’ of misinformation, there have been surprisingly few achievements to celebrate,” said Ayers, who is vice chief of innovation in the Division of Infectious Disease and Global Public Health at UC San Diego School of Medicine and Deputy Director of Informatics at the Altman Clinical and Translational Research Institute in addition to Qualcomm Institute scientist. “X’s Community Notes have emerged as an innovative solution, pushing back with accurate and credible health information.” 

Understanding Social Media Misinformation Countermeasures

Before the inception of Community Notes, social media companies employed various tactics to tackle misinformation, including censoring, shadowbanning (muting a user or their content on a platform without informing them), and adding generic warning labels to problematic content. “However, social media companies have been unwilling to disclose details of the inner workings of their efforts against misinformation or to share the necessary data to study their utility,” said Mathew Allen, study co-author and UC San Diego medical student. 

In late 2022, X introduced Community Notes—a paradigm shift in the fight against misinformation. This novel approach empowers volunteer, independent, anonymous, and ideologically diverse contributors to identify posts containing misinformation and to rectify misinformation by appending informative “notes” to suspect posts. The process is controlled by the public, instead of decision-makers at the company.

“Because Community Notes is a uniquely open-sourced misinformation countermeasure, it can be studied and improved using the scientific method,” added Allen. 

Evaluating X’s Community Notes

The research team obtained all notes that mentioned terms related to vaccines or COVID along with their corresponding posts made during the first year of the Community Notes program, from December 12, 2022, through December 12, 2023. Of 45,783 notes, 657 address COVID-19 vaccination, with the monthly rate of notes increasing from 22 to 186 during the study. 

A team of evaluators working with an infectious disease physician and virologist evaluated the subject, accuracy, and source credibility of randomly sampled notes. Of the notes examined, 51% addressed adverse events attributed to COVID-19 vaccination; 37%, conspiracy theories; 7%, vaccine recommendations; and 5% vaccine effectiveness. In terms of accuracy, 97.5% of notes were entirely accurate; 2%, partially accurate, meaning they addressed scientifically debated conclusions; and 0.5%, inaccurate. In terms of sources, 49% of notes cited highly credible sources (such as primary data sources, like peer-reviewed studies); 44%, moderately credible sources (such as major news outlets or fact checkers); and 7%, low credibility sources (such as blogs or tabloids).

“Notes typically addressed obvious misinformation, offering corrections from credible sources,” said Nimit Desai, a study co-author and UC San Diego medical student. “It’s remarkable to witness the online community’s adeptness in steering conversations towards accurate and high-quality evidence when provided with the right tools.”

The sample of notes studied was attached to posts that averaged 1,064,981 views, extrapolating to between 500 million and 1 billion views for all COVID-19 vaccination-related posts noted. 

“Our study shifts the focus from talking about misinformation to taking action, offering practical insights into social media strategies that protect public health,” explained Mark Dredze, Ph.D., the John C Malone Professor of Computer Science at Johns Hopkins University and study co-author. “Although we couldn’t examine how these notes directly influenced people’s beliefs or actions, the characteristics we analyzed have consistently been shown to predict a message’s effectiveness.”

Learning from and Enhancing X’s Community Notes

U.S. Food and Drug Administration Commissioner Robert Califf recently argued vaccination is approaching a dangerous tipping point because of social media misinformation. “One viable avenue for the public health community to combat this threat is to actively engage in social media-based interventions, such as Community Notes,” said physician-scientist and study co-author Davey Smith, M.D., chief of the Division of Infectious Disease and Global Public Health and professor in the UC San Diego School of Medicine, co-director of the Altman Clinical and Translational Research Institute at UC San Diego, and immunologist at UC San Diego Health. “While only a fraction of vaccine misinformation posts are currently addressed, the ample room for expansion suggests significant opportunities to amplify the impact of Community Notes.”

Eric Leas, Ph.D., co-author of the study, assistant professor at the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and Qualcomm Institute affiliate, highlighted the transformative role of Community Notes in combating misinformation. “Rather than censoring misleading content, Community Notes fosters a learning environment where users can glean insights from corrections to misinformation to prevent similar misunderstandings in the future. By providing context and credible sources alongside contentious posts, the platform empowers users to discern fact from fiction, a skill they will find useful as they navigate all claims.”

Ayers concluded, “Other social media platforms should embrace transparency by open-sourcing their misinformation countermeasures. This step is crucial for enabling independent scientific scrutiny, which will enhance public trust in and amplify adoption of the most impactful strategies.”

In addition to Ayers, Allen, Desai, Leas, Dredze, and Smith, authors of the JAMA paper, “Characteristics of X’s (Twitter) Community Notes Addressing COVID-19 Vaccine Misinformation” (JAMA doi:10.1001/jama.2024.4800), include Aiden Namazi, a student research intern at UC San Diego’s Qualcomm Institute.


Read More

Continue Reading

Government

WTI Jumps After Bigger-Than-Expected Crude Inventory Build, Gasoline Demand (Reportedly) Slumps

WTI Jumps After Bigger-Than-Expected Crude Inventory Build, Gasoline Demand (Reportedly) Slumps

Oil prices are drifting lower this morning,…

Published

on

WTI Jumps After Bigger-Than-Expected Crude Inventory Build, Gasoline Demand (Reportedly) Slumps

Oil prices are drifting lower this morning, despite API reporting a surprise crude inventory draw last night, as hopes that geopolitical tensions are easing (hope is not a strategy) combined with a reduced expectation of economy-juicing rate-cuts are weighing on crude prices.

Supporting the upside, the US Senate, meanwhile, passed tougher measures against Iran in response to its attack on Israel earlier this month, with President Joe Biden saying he’ll sign the legislation into law. But the market is clearly calling Biden's bluff on this threat as he faces soaring pump prices domestically which will do nothing to help his "but I fixed inflation" narrative into the election...

Source: Bloomberg

However, for now, all eyes are on the official inventory and supply data for any signs of overall tightness, and refined products demand as the summer driving season is fast approaching.

API

  • Crude -3.23mm (+500k exp)

  • Cushing -898k

  • Gasoline -595k (-1.5mm exp)

  • Distillates +724k (-1.0mm exp)

DOE

  • Crude -6.4mm (+500k exp)

  • Cushing -659k

  • Gasoline -634k (-1.5mm exp)

  • Distillates +1.6mm (-1.0mm exp)

Confirming API's report, the official data showed crude inventories plunging last week by the most since January. On the product side, it was mixed with gasoline drawing down by distillates building...

Source: Bloomberg

There was a 909k b/d drop in the adjustment factor versus last week, the biggest decline since February, coinciding with the big increase in crude exports. At 257k b/d this week’s balancing measure was pretty small by its own highly volatile standards.

Source: Bloomberg

The Biden admin added 793k barrels to the SPR last week - the largest addition since January... and probably the last!

Source: Bloomberg

Implied gasoline demand fell yet again, nearly slipping back below 2022 seasonal levels for the first time since early March.

The figure typically sees decent growth at this point in the year, yet a post-Spring Break slump appears to have become the norm since 2020.

In comparison to pre-pandemic demand, the figure is at its lowest since 2014.

Source: Bloomberg

US crude production was flat at 13.1mm b/d (near record highs) and we note a very modest rise in rig count trends starting...

Source: Bloomberg

WTI was trading around $83.00 ahead of the API data and jumped back into the green for the day after the crude draw...

The conflict in the Middle East has "undoubtedly exacerbated tensions in an already volatile region," Stephen Innes, managing partner at SPI Asset Management, told MarketWatch.

"While the recent attacks have been downplayed, the potential for further escalation cannot be entirely dismissed."

However, "there's a lesson to be gleaned from this situation, particularly in how swiftly demand responded to higher oil and gasoline prices, as evidenced by the increase in U.S. oil stockpiles," he said.

Finally, timespreads are signaling tighter conditions, with the gap between Brent’s two nearest contracts widening to $1.05 a barrel in backwardation, a bullish pattern in which the nearer contract trades at a premium to the next in sequence. That compares with 69 cents a week ago.

Tyler Durden Wed, 04/24/2024 - 10:38

Read More

Continue Reading

Trending